AR030551A1 - Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante - Google Patents

Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante

Info

Publication number
AR030551A1
AR030551A1 ARP010100761A ARP010100761A AR030551A1 AR 030551 A1 AR030551 A1 AR 030551A1 AR P010100761 A ARP010100761 A AR P010100761A AR P010100761 A ARP010100761 A AR P010100761A AR 030551 A1 AR030551 A1 AR 030551A1
Authority
AR
Argentina
Prior art keywords
nefiracetam
composition
neurodegeneration
manufacture
processing
Prior art date
Application number
ARP010100761A
Other languages
English (en)
Spanish (es)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of AR030551A1 publication Critical patent/AR030551A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ARP010100761A 2000-02-23 2001-02-21 Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante AR030551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51195200A 2000-02-23 2000-02-23

Publications (1)

Publication Number Publication Date
AR030551A1 true AR030551A1 (es) 2003-08-27

Family

ID=24037094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100761A AR030551A1 (es) 2000-02-23 2001-02-21 Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante

Country Status (20)

Country Link
US (2) US6423739B1 (enExample)
EP (1) EP1171123B1 (enExample)
JP (1) JP2003523385A (enExample)
KR (1) KR20010110798A (enExample)
CN (1) CN1362877A (enExample)
AR (1) AR030551A1 (enExample)
AT (1) ATE336246T1 (enExample)
AU (1) AU784418B2 (enExample)
BR (1) BR0104586A (enExample)
CA (1) CA2368352C (enExample)
DE (1) DE60122252T2 (enExample)
DK (1) DK1171123T3 (enExample)
ES (1) ES2270981T3 (enExample)
HK (1) HK1047038A1 (enExample)
ID (1) ID30377A (enExample)
IL (1) IL145799A (enExample)
MX (1) MXPA01010749A (enExample)
NO (1) NO321911B1 (enExample)
TW (1) TWI289060B (enExample)
WO (1) WO2001062246A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration
RU2205631C1 (ru) * 2002-06-19 2003-06-10 Закрытое акционерное общество "Брынцалов-А" Ноотропное средство "ноотобрил" в форме таблеток
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
ES2664727T3 (es) 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469995A (en) * 1946-07-23 1949-05-10 Schaul Martin Carl Process for the production of food preparations from potatoes and similar farinaceoustubers
US3031314A (en) * 1960-03-16 1962-04-24 Carl E Hendel Preparation of dehydrated potatoes
US3260607A (en) * 1961-02-07 1966-07-12 Canadian Patents Dev Preparation of dehydrated cooked mashed potato
US3968265A (en) * 1973-02-01 1976-07-06 American Potato Company Freeze-thaw stable, french fry potato product and process for producing the same
DE2924011C2 (de) 1979-06-13 1982-04-08 A. Nattermann & Cie GmbH, 5000 Köln Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten
DE2923975A1 (de) 1979-06-13 1980-12-18 Nattermann A & Cie Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel
IT1141287B (it) 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
SK279285B6 (sk) 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5525058A (en) 1992-03-27 1996-06-11 American Dental Technologies, Inc. Dental treatment system
KR100232929B1 (ko) 1995-07-10 1999-12-01 히로지 코데라 가공 선재의 접속 장치
US6107330A (en) 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
ES2185963T3 (es) 1996-07-30 2003-05-01 Ecolab Gmbh & Co Ohg Agente filmogeno para la proteccion contra infecciones.
EP0953356A4 (en) 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
US6211701B1 (en) 1996-12-16 2001-04-03 Rose Research, Llc Low power line switching circuit, device and method
IT1293533B1 (it) 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
AU8131198A (en) 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
AR020115A1 (es) 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
KR20020015321A (ko) 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제

Also Published As

Publication number Publication date
US20020055534A1 (en) 2002-05-09
IL145799A (en) 2006-10-31
AU3414501A (en) 2001-09-03
ES2270981T3 (es) 2007-04-16
BR0104586A (pt) 2002-01-08
DK1171123T3 (da) 2006-12-04
ID30377A (id) 2001-11-29
IL145799A0 (en) 2002-07-25
WO2001062246A1 (en) 2001-08-30
KR20010110798A (ko) 2001-12-13
AU784418B2 (en) 2006-03-30
NO20015162L (no) 2001-12-21
DE60122252T2 (de) 2007-07-05
US6399650B2 (en) 2002-06-04
CN1362877A (zh) 2002-08-07
NO321911B1 (no) 2006-07-17
DE60122252D1 (de) 2006-09-28
JP2003523385A (ja) 2003-08-05
EP1171123A1 (en) 2002-01-16
US6423739B1 (en) 2002-07-23
HK1047038A1 (zh) 2003-02-07
CA2368352A1 (en) 2001-08-30
ATE336246T1 (de) 2006-09-15
TWI289060B (en) 2007-11-01
CA2368352C (en) 2009-11-10
NO20015162D0 (no) 2001-10-22
MXPA01010749A (es) 2002-08-20
EP1171123B1 (en) 2006-08-16
US20010051653A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
WO2005046640A3 (en) Multi-site drug delivery platform
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
DE602004032149D1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
RU2002122084A (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных растройств
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
WO2006072940A3 (en) Controlled long acting release pharmaceutical preparation for use in the oral cavity
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
RU2005105302A (ru) Композиция бицифадина
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
CA2457982A1 (en) Use of nefiracetam for treating neurodegeneration
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги

Legal Events

Date Code Title Description
FB Suspension of granting procedure